BC Extra | Oct 23, 2003
Financial News

Invitrogen beats Street EPS

Research tool supplier IVGN reported third quarter EPS of $0.57, beating the Street consensus estimate by $0.05 and up 24% from $0.46 for the same period last year. Revenues for the quarter came in at...
BioCentury | Jul 7, 2003
Finance

Invitrogen acquisitions

Invitrogen acquisitions Proposed Company Cash amount Acquisition rev (prior year) IVGN cash pre-deal Oct '02 InforMax $42M $25.2M $704.3M (3Q02) Feb '03 PanVera (Vertex subsidiary) $95M NA $722.0M (4Q02) Jul '03 Molecular Probes $325M $56M...
BC Week In Review | May 26, 2003
Company News

Vitra Biosciences Inc. management update

Vitra Biosciences Inc. , Sunnyvale, Calif.   Business: Supply/Service, Microarrays, Computational chemistry/biology   Hired: Andrew Whitely as CEO, president and a director, formerly chairman and CEO of InforMax Inc.  ...
BioCentury | Nov 18, 2002
Finance

M&A crystal ball

At least six biotech companies will disappear as the result of M&A activity last week, leading some to wonder whether the oft-talked about consolidation is upon us. The answer: don't bank on it. Even though...
BC Week In Review | Oct 21, 2002
Company News

InforMax, Invitrogen deal

Research tool provider IVGN will acquire INMX for $42 million in cash, valuing INMX at $1.36 per share. INMX has $47 million in cash and investments and expects a cash position of about $41 million...
BioCentury | Oct 21, 2002
Finance

Ebb & Flow

Investors typically move into defensive stocks such as healthcare when the general economy gets glum, on the presumption that disease and malady know no recession. But with the bear market running well into its second...
BC Extra | Oct 15, 2002
Company News

Invitrogen acquiring InforMax

Research tool provider IVGN will acquire INMX for $42 million in cash, valuing INMX at $1.36 per share - a 143% premium to INMX's Monday close at $0.56. INMX has $47 million in cash and investments...
BC Week In Review | Oct 14, 2002
Company News

InforMax sales and marketing update

INMX launched its Vector PathBlazer software application for integrating biological pathway and protein-protein interaction data. InforMax Inc. (INMX), Bethesda, Md.   Business: Bioinformatics  ...
BC Week In Review | Oct 7, 2002
Company News

InforMax, SciTegic Inc. deal

The companies partnered to combine SciTegic's Pipeline Pilot drug discovery informatics software with INMX's Vector informatics products for data access and mining. InforMax Inc. (INMX), Bethesda, Md.   SciTegic Inc. , San Diego, Calif.   Business:...
BC Week In Review | Sep 23, 2002
Company News

InforMax sales and marketing update

INMX launched its Vector Xpression software for microarray gene expression data analysis. INMX also launched its Vector NTI Advance software for protein and DNA sequence analysis and molecular biology information management. InforMax Inc. (INMX), Bethesda,...
Items per page:
1 - 10 of 69
BC Extra | Oct 23, 2003
Financial News

Invitrogen beats Street EPS

Research tool supplier IVGN reported third quarter EPS of $0.57, beating the Street consensus estimate by $0.05 and up 24% from $0.46 for the same period last year. Revenues for the quarter came in at...
BioCentury | Jul 7, 2003
Finance

Invitrogen acquisitions

Invitrogen acquisitions Proposed Company Cash amount Acquisition rev (prior year) IVGN cash pre-deal Oct '02 InforMax $42M $25.2M $704.3M (3Q02) Feb '03 PanVera (Vertex subsidiary) $95M NA $722.0M (4Q02) Jul '03 Molecular Probes $325M $56M...
BC Week In Review | May 26, 2003
Company News

Vitra Biosciences Inc. management update

Vitra Biosciences Inc. , Sunnyvale, Calif.   Business: Supply/Service, Microarrays, Computational chemistry/biology   Hired: Andrew Whitely as CEO, president and a director, formerly chairman and CEO of InforMax Inc.  ...
BioCentury | Nov 18, 2002
Finance

M&A crystal ball

At least six biotech companies will disappear as the result of M&A activity last week, leading some to wonder whether the oft-talked about consolidation is upon us. The answer: don't bank on it. Even though...
BC Week In Review | Oct 21, 2002
Company News

InforMax, Invitrogen deal

Research tool provider IVGN will acquire INMX for $42 million in cash, valuing INMX at $1.36 per share. INMX has $47 million in cash and investments and expects a cash position of about $41 million...
BioCentury | Oct 21, 2002
Finance

Ebb & Flow

Investors typically move into defensive stocks such as healthcare when the general economy gets glum, on the presumption that disease and malady know no recession. But with the bear market running well into its second...
BC Extra | Oct 15, 2002
Company News

Invitrogen acquiring InforMax

Research tool provider IVGN will acquire INMX for $42 million in cash, valuing INMX at $1.36 per share - a 143% premium to INMX's Monday close at $0.56. INMX has $47 million in cash and investments...
BC Week In Review | Oct 14, 2002
Company News

InforMax sales and marketing update

INMX launched its Vector PathBlazer software application for integrating biological pathway and protein-protein interaction data. InforMax Inc. (INMX), Bethesda, Md.   Business: Bioinformatics  ...
BC Week In Review | Oct 7, 2002
Company News

InforMax, SciTegic Inc. deal

The companies partnered to combine SciTegic's Pipeline Pilot drug discovery informatics software with INMX's Vector informatics products for data access and mining. InforMax Inc. (INMX), Bethesda, Md.   SciTegic Inc. , San Diego, Calif.   Business:...
BC Week In Review | Sep 23, 2002
Company News

InforMax sales and marketing update

INMX launched its Vector Xpression software for microarray gene expression data analysis. INMX also launched its Vector NTI Advance software for protein and DNA sequence analysis and molecular biology information management. InforMax Inc. (INMX), Bethesda,...
Items per page:
1 - 10 of 69